Clover Health Investments (NASDAQ:CLOV – Get Free Report) and Standard BioTools (NASDAQ:LAB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.
Analyst Ratings
This is a summary of current ratings and price targets for Clover Health Investments and Standard BioTools, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Clover Health Investments | 1 | 3 | 1 | 0 | 2.00 |
| Standard BioTools | 1 | 3 | 0 | 0 | 1.75 |
Clover Health Investments presently has a consensus price target of $3.23, indicating a potential upside of 42.44%. Standard BioTools has a consensus price target of $1.35, indicating a potential downside of 4.26%. Given Clover Health Investments’ stronger consensus rating and higher probable upside, analysts plainly believe Clover Health Investments is more favorable than Standard BioTools.
Risk & Volatility
Profitability
This table compares Clover Health Investments and Standard BioTools’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Clover Health Investments | -3.29% | -16.79% | -9.95% |
| Standard BioTools | -86.06% | -20.89% | -15.98% |
Valuation and Earnings
This table compares Clover Health Investments and Standard BioTools”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Clover Health Investments | $1.37 billion | 0.86 | -$43.01 million | ($0.11) | -20.64 |
| Standard BioTools | $174.43 million | 3.11 | -$138.88 million | ($0.34) | -4.15 |
Clover Health Investments has higher revenue and earnings than Standard BioTools. Clover Health Investments is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
19.8% of Clover Health Investments shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 24.1% of Clover Health Investments shares are held by company insiders. Comparatively, 23.2% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Clover Health Investments beats Standard BioTools on 11 of the 14 factors compared between the two stocks.
About Clover Health Investments
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.
About Standard BioTools
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Receive News & Ratings for Clover Health Investments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clover Health Investments and related companies with MarketBeat.com's FREE daily email newsletter.
